BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10940690)

  • 1. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.
    Smith MC; Liu J; Chen T; Schran H; Yeh CM; Jamar F; Valkema R; Bakker W; Kvols L; Krenning E; Pauwels S
    Digestion; 2000; 62 Suppl 1():69-72. PubMed ID: 10940690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
    Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide receptor imaging and therapy.
    Kwekkeboom D; Krenning EP; de Jong M
    J Nucl Med; 2000 Oct; 41(10):1704-13. PubMed ID: 11038002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases.
    Bushnell D; Menda Y; Madsen M; O'Dorisio T; Carlisle T; Zehr P; Ponto L; Karwal M; Parker S; Ponto J; Connolly M; Bouterfa H
    Cancer Biother Radiopharm; 2003 Aug; 18(4):581-8. PubMed ID: 14503953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.
    Virgolini I; Britton K; Buscombe J; Moncayo R; Paganelli G; Riva P
    Semin Nucl Med; 2002 Apr; 32(2):148-55. PubMed ID: 11965610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
    Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
    Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
    Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
    Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
    Kaltsas GA; Papadogias D; Makras P; Grossman AB
    Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
    Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
    Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.
    Bodei L; Cremonesi M; Grana C; Rocca P; Bartolomei M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):1038-46. PubMed ID: 15150675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.